Aliases & Classifications for Migraine with Aura

Aliases & Descriptions for Migraine with Aura:

Name: Migraine with Aura 12 29 42 14 69
Migraine with Typical Aura 69
Classic Migraine 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10024
ICD9CM 35 346.0
MeSH 42 D020325
NCIt 47 C117005
SNOMED-CT 64 155047002 4473006
UMLS 69 C0154723

Summaries for Migraine with Aura

Disease Ontology : 12 A migraine characterized by migraine headache which is preceded or accompanied by a transient focal neurological phenomenon.

MalaCards based summary : Migraine with Aura, also known as migraine with typical aura, is related to migraine with aura 9 and migraine with aura 7, and has symptoms including headache An important gene associated with Migraine with Aura is KCNK18 (Potassium Two Pore Domain Channel Subfamily K Member 18), and among its related pathways/superpathways are cAMP signaling pathway and Calcium signaling pathway. The drugs Sumatriptan and Naproxen have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Migraine with Aura

Diseases in the Migraine with Aura family:

Migraine with Aura 9 Migraine with Aura 7

Diseases related to Migraine with Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
id Related Disease Score Top Affiliating Genes
1 migraine with aura 9 12.1
2 migraine with aura 7 12.1
3 hemiplegic migraine 11.3
4 familial hemiplegic migraine 11.3
5 migraine, familial hemiplegic, 1 11.1
6 migraine, familial hemiplegic, 2 11.1
7 migraine with or without aura 1 11.1
8 epilepsy, familial temporal lobe, 4 11.0
9 migraine, with or without aura 13 11.0
10 migraine, familial hemiplegic, 3 11.0
11 headache 10.4
12 cerebritis 10.3
13 patent foramen ovale 10.3
14 familial or sporadic hemiplegic migraine 10.2
15 intracranial cavernous angioma 10.2 DRD2 SLC6A4
16 splenic abscess 10.2 DRD2 SLC6A4
17 ornithosis 10.2 DRD2 SLC6A4
18 dry eye syndrome 10.2 HTR2C SLC6A4
19 euthyroid sick syndrome 10.2 DRD2 SLC6A4
20 kartagener syndrome 10.2 ACE MTHFR
21 pars planitis 10.1 ACE MTHFR
22 anodontia 10.1 HTR2C SLC6A4
23 apperceptive agnosia 10.1 DRD2 SLC6A4
24 infantile hypotonia 10.1 ATP1A2 CACNA1A EDNRA
25 bullous skin disease 10.1 ACE MTHFR
26 renpenning syndrome 10.1 DBH SLC6A4
27 pyromania 10.1 DRD2 SLC6A4
28 waardenburg's syndrome 10.1 DRD2 HTR2C SLC6A4
29 cecal benign neoplasm 10.1 DRD2 HTR2C SLC6A4
30 cholesteatoma 10.1 DRD2 HTR2C SLC6A4
31 restless legs syndrome 10.1
32 arteriovenous malformation 10.1
33 endotheliitis 10.1
34 microscopic colitis 10.0 ATP1A2 CACNA1A NOTCH3
35 retinoblastoma 10.0 DRD2 HTR2C SLC6A4
36 benign epilepsy with centrotemporal spikes 10.0 DRD2 HTR2C SLC6A4
37 personality disorder 10.0 DRD2 HTR2C SLC6A4
38 colorectal adenocarcinoma 10.0 DBH DRD2 SLC6A4
39 nephrogenic adenoma of the urethra 10.0 DBH DRD2 SLC6A4
40 cytomegalic congenital adrenal hypoplasia 10.0 DBH DRD2 SLC6A4
41 transmitted_by 10.0 DBH DRD2 SLC6A4
42 mucinous adenocarcinoma 10.0 DBH DRD2 SLC6A4
43 atrial fibrillation and stroke 10.0 ATP1A2 CACNA1A PRRT2
44 acro-pectoro-renal dysplasia 10.0 ATP1A2 CACNA1A PRRT2
45 placental abruption 10.0 ATP1A2 CACNA1A PRRT2
46 contagious pustular dermatitis 9.9 ACE MTHFR NOTCH3
47 gaba aminotransferase deficiency 9.9 ATP1A2 PRRT2
48 cervix small cell carcinoma 9.9 ACE MTHFR NOTCH3
49 cadasil 9.9
50 cluster headache 9.9

Comorbidity relations with Migraine with Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with Aura:



Diseases related to Migraine with Aura

Symptoms & Phenotypes for Migraine with Aura

UMLS symptoms related to Migraine with Aura:


headache

MGI Mouse Phenotypes related to Migraine with Aura:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 EDNRA HTR2C NOTCH3 PRRT2 SLC6A4 ACE
2 homeostasis/metabolism MP:0005376 10.07 ACE ATP1A2 CACNA1A DBH DRD2 EDNRA
3 growth/size/body region MP:0005378 10.06 ACE CACNA1A DBH DRD2 EDNRA HTR2C
4 cardiovascular system MP:0005385 10 ACE ATP1A2 DBH DRD2 EDNRA NOTCH3
5 endocrine/exocrine gland MP:0005379 9.98 DBH DRD2 EDNRA NOTCH3 SLC6A4 ACE
6 integument MP:0010771 9.97 ATP1A2 CACNA1A DBH DRD2 EDNRA HTR2C
7 mortality/aging MP:0010768 9.96 SLC6A4 HTR2C MTHFR NOTCH3 ACE ATP1A2
8 muscle MP:0005369 9.7 ATP1A2 CACNA1A DRD2 EDNRA HTR2C NOTCH3
9 nervous system MP:0003631 9.7 ATP1A2 CACNA1A DBH DRD2 EDNRA HTR2C
10 normal MP:0002873 9.17 ATP1A2 CACNA1A DBH DRD2 EDNRA NOTCH3

Drugs & Therapeutics for Migraine with Aura

Drugs for Migraine with Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sumatriptan Approved, Investigational Phase 4,Phase 3,Phase 2 103628-46-2 5358
2
Naproxen Approved, Vet_approved Phase 4,Phase 3 22204-53-1 1302 156391
3
Milnacipran Approved Phase 4 92623-85-3 65833
4
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
5
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
6
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
7
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3 525-66-6 4946
8
Topiramate Approved Phase 4,Phase 3,Phase 2 97240-79-4 5284627
9
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
10
Rizatriptan Approved Phase 4,Phase 3 145202-66-0, 144034-80-0 5078
11
Almotriptan Approved, Investigational Phase 4,Phase 3 154323-57-6, 181183-52-8 123606
12
Eletriptan Approved, Investigational Phase 4,Phase 3 143322-58-1 77993
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
14 Analgesics Phase 4,Phase 3,Phase 2
15
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
16 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Phase 2
17 Serotonin Agents Phase 4,Phase 3,Phase 2
18 Adrenergic Agents Phase 4,Phase 2,Phase 3
19 Serotonin Uptake Inhibitors Phase 4
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
22 Neurotransmitter Uptake Inhibitors Phase 4
23 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
26 Vasodilator Agents Phase 4,Phase 2,Phase 3,Early Phase 1
27 Antidepressive Agents Phase 4,Phase 2
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
29 Psychotropic Drugs Phase 4,Phase 2
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2
32 Adjuvants, Anesthesia Phase 4
33 Narcotics Phase 4
34 Adrenergic Antagonists Phase 4,Phase 2,Phase 3
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
36 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
37 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 3
38 Analgesics, Opioid Phase 4
39 Anesthetics Phase 4,Phase 3
40 Anesthetics, General Phase 4
41 Anesthetics, Intravenous Phase 4
42 Dopamine Agents Phase 4,Phase 3,Phase 2
43 Dopamine Antagonists Phase 4,Phase 3,Phase 2
44 Dopamine D2 Receptor Antagonists Phase 4,Phase 3
45 Pharmaceutical Solutions Phase 4
46 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
47 Anticonvulsants Phase 4,Phase 3,Phase 2
48 Protective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
49 Antiemetics Phase 4,Phase 3,Phase 2
50 Antihypertensive Agents Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 149)
id Name Status NCT ID Phase
1 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4
2 Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department Completed NCT01596166 Phase 4
3 Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine Completed NCT00210496 Phase 4
4 Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Completed NCT00212810 Phase 4
5 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4
6 Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds Completed NCT02287376 Phase 4
7 A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Completed NCT00792636 Phase 4
8 Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs Completed NCT00634985 Phase 4
9 A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache Completed NCT00210509 Phase 4
10 An Efficacy and Tolerability Study of Topiramate in Participants With Migraine Completed NCT01060111 Phase 4
11 Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms. Completed NCT00753311 Phase 4
12 Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex Completed NCT01450995 Phase 4
13 The Coherex FlatStent™ EF PFO Migraine Registry Unknown status NCT01280578 Phase 3
14 MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant Unknown status NCT00283738 Phase 2, Phase 3
15 Acupuncture for Migraine Prophylaxis Unknown status NCT01687660 Phase 2, Phase 3
16 Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura Completed NCT00449540 Phase 3
17 Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study Completed NCT01859481 Phase 3
18 Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3
19 Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine Completed NCT01741714 Phase 3
20 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment Completed NCT01814189 Phase 3
21 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3
22 Candesartan Versus Propranolol for Migraine Prevention Completed NCT00884663 Phase 2, Phase 3
23 A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine Completed NCT00236509 Phase 3
24 A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine Completed NCT00236561 Phase 3
25 A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine Completed NCT00231595 Phase 3
26 Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00131443 Phase 2, Phase 3
27 Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study Completed NCT00258609 Phase 3
28 A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3) Completed NCT01004263 Phase 3
29 Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) Completed NCT00442936 Phase 3
30 Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura Completed NCT01667679 Phase 3
31 TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1) Completed NCT00387881 Phase 3
32 Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study Completed NCT01986088 Phase 3
33 Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) Completed NCT00483704 Phase 3
34 Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan Completed NCT01989936 Phase 3
35 Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) Completed NCT00443209 Phase 3
36 Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016) Completed NCT00432237 Phase 3
37 Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine Completed NCT01978496 Phase 3
38 Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine Completed NCT01462812 Phase 3
39 A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents Completed NCT00210483 Phase 3
40 Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo Completed NCT01986270 Phase 3
41 An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack Completed NCT00330850 Phase 3
42 A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Completed NCT00382993 Phase 3
43 A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087) Completed NCT00894556 Phase 3
44 A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Completed NCT00383162 Phase 3
45 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines Completed NCT00122278 Phase 3
46 Migraine Study in Adolescent Patients Completed NCT00843024 Phase 3
47 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Recruiting NCT02828020 Phase 3
48 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Recruiting NCT02867709 Phase 3
49 Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention Recruiting NCT02848326 Phase 2, Phase 3
50 Efficacy, Tolerability, and Safety of DFN-15 Recruiting NCT03009019 Phase 3

Search NIH Clinical Center for Migraine with Aura

Cochrane evidence based reviews: migraine with aura

Genetic Tests for Migraine with Aura

Genetic tests related to Migraine with Aura:

id Genetic test Affiliating Genes
1 Migraine with Aura 29

Anatomical Context for Migraine with Aura

MalaCards organs/tissues related to Migraine with Aura:

39
Brain, Cortex, Testes, Endothelial, Heart, Liver, Pituitary

Publications for Migraine with Aura

Articles related to Migraine with Aura:

(show top 50) (show all 349)
id Title Authors Year
1
Migraine with Aura or Sports-Related Concussion: Case Report, Pathophysiology, and Multidisciplinary Approach to Management. ( 28067735 )
2017
2
Can the border of migraine with aura be safely extended? ( 27152015 )
2016
3
Frequency of pediatric migraine with aura in a clinic-based sample. ( 26790850 )
2016
4
Rare Complications of Migraine With Aura. ( 27400397 )
2016
5
Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. ( 26908949 )
2016
6
The effect of 1A mg folic acid supplementation on clinical outcomes in female migraine with aura patients. ( 27339806 )
2016
7
De Novo Migraine With Aura After Surgical Repair of Aortic Coarctation. ( 27910096 )
2016
8
High leptin levels are associated with migraine with aura. ( 27165492 )
2016
9
Patent Foramen Ovale With Atrial Septal Aneurysm Is Strongly Associated With Migraine With Aura: A Large Observational Study. ( 27930349 )
2016
10
Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk? ( 27774589 )
2016
11
Relationship between primary restless legs syndrome and migraine with aura. ( 27523456 )
2016
12
Addenbrooke's cognitive examination test for brief cognitive assessment of adolescents suffering from migraine with aura. ( 27255917 )
2016
13
White matter lesion burden in migraine with aura may be associated with reduced cerebral blood flow. ( 27177583 )
2016
14
Transient Splenial Lesion of the Corpus Callosum Related to Migraine with Aura in a Pediatric Patient. ( 27526308 )
2016
15
Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. ( 27190013 )
2016
16
Stromal Cell-Derived Factor-1 Alpha Is Decreased in Women With Migraine With Aura. ( 27238143 )
2016
17
Endothelial function in migraine with aura - a systematic review. ( 25546573 )
2015
18
Visual Snow in Migraine With Aura: Further Characterization by Brain Imaging, Electrophysiology, and Treatment - Case Report. ( 26307008 )
2015
19
Reduced efficacy of sumatriptan in migraine with aura vs without aura. ( 25841032 )
2015
20
Gene-based pleiotropy across migraine with aura and migraine without aura patient groups. ( 26660531 )
2015
21
Increased interictal visual network connectivity in patients with migraine with aura. ( 25926619 )
2015
22
Variability of clinical features in attacks of migraine with aura. ( 25944814 )
2015
23
Cortical hot spots and labyrinths: why cortical neuromodulation for episodic migraine with aura should be personalized. ( 25798103 )
2015
24
Statins for all: should patients who have migraine with aura be on a statin? ( 26500300 )
2015
25
Vitamin Supplementation as Possible Prophylactic Treatment against Migraine with Aura and Menstrual Migraine. ( 25815319 )
2015
26
Recurrence of Migraine With Aura After a 24-year Free Period Following rTMS Treatment for Fibromyalgia Pain. ( 26358488 )
2015
27
Migraine with aura and patent foramen ovale: myth or reality? ( 26017514 )
2015
28
Investigations of functional and structural changes in migraine with aura by magnetic resonance imaging. ( 26239598 )
2015
29
Migraine with aura and TCD bubble-test: The significance of positive result. ( 26495697 )
2015
30
No abnormalities of intrinsic brain connectivity in the interictal phase of migraine with aura. ( 25573335 )
2015
31
Visual evoked potentials in subgroups of migraine with aura patients. ( 26527348 )
2015
32
Reduced functional connectivity between salience and visual networks in migraine with aura. ( 25888585 )
2015
33
Abnormal Connectivity Within Executive Resting-State Network in Migraine With Aura. ( 26084236 )
2015
34
Incidences of aortic and mitral valve strands in patients with migraine with aura. ( 25936701 )
2015
35
Migraine with aura: which patients are most at risk of stroke? ( 26017513 )
2015
36
Efficacy of frovatriptan as compared to other triptans in migraine with aura. ( 25916333 )
2015
37
Our evolving understanding of migraine with aura. ( 25230799 )
2014
38
Impaired visual inhibition in migraine with aura. ( 25586129 )
2014
39
Prolonged acute migraine with aura and reversible brain MRI abnormalities after liquid sclerotherapy. ( 24948446 )
2014
40
Multimodal assessment of optokinetic visual stimulation response in migraine with aura. ( 23980899 )
2014
41
Retinal nerve fibre layer, ganglion cell layer and choroid thinning in migraine with aura. ( 24885597 )
2014
42
Framing comorbidities and co-occurrences in a migraine with aura patient. ( 24852063 )
2014
43
Perfusion patterns in migraine with aura. ( 24554619 )
2014
44
A challenging multifactorial migraine with aura. ( 24419740 )
2014
45
Circulating microparticles in migraine with aura: Cause or consequence, a link to stroke. ( 24715499 )
2014
46
The effects of topiramate therapy on cerebral metabolism in migraine with aura patients. ( 25269040 )
2014
47
Association between serum levels of homocysteine with characteristics of migraine attacks in migraine with aura. ( 25657748 )
2014
48
Migraine with aura is associated with impaired colour vision: Results from the cross-sectional German DMKG headache study. ( 25179294 )
2014
49
Should women suffering from migraine with aura be screened for biological thrombophilia?: results from a cross-sectional French study. ( 24530211 )
2014
50
Acetylsalicylic Acid in migraine with aura prevention - a retrospective study. ( 25729594 )
2014

Variations for Migraine with Aura

Expression for Migraine with Aura

Search GEO for disease gene expression data for Migraine with Aura.

Pathways for Migraine with Aura

Pathways related to Migraine with Aura according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.85 ATP1A2 DRD2 EDNRA
2
Show member pathways
11.77 CACNA1A EDNRA HTR2C
3
Show member pathways
11.19 ATP1A2 CACNA1A SLC6A4
4 10.85 CACNA1A HTR2C SLC6A4
5 10.7 HTR2C SLC6A4
6 10.52 CACNA1A DBH

GO Terms for Migraine with Aura

Cellular components related to Migraine with Aura according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.9 ACE ATP1A2 CACNA1A DBH DRD2 EDNRA
2 plasma membrane GO:0005886 9.65 ACE ATP1A2 CACNA1A DRD2 EDNRA HTR2C
3 integral component of membrane GO:0016021 9.36 ACE ATP1A2 CACNA1A DBH DRD2 EDNRA

Biological processes related to Migraine with Aura according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.67 DRD2 HTR2C MTHFR SLC6A4
2 release of sequestered calcium ion into cytosol GO:0051209 9.57 DRD2 HTR2C
3 blood vessel remodeling GO:0001974 9.56 ACE DBH
4 adult walking behavior GO:0007628 9.55 CACNA1A DRD2
5 associative learning GO:0008306 9.54 DBH DRD2
6 response to amphetamine GO:0001975 9.52 DBH DRD2
7 arachidonic acid secretion GO:0050482 9.51 ACE DRD2
8 locomotory behavior GO:0007626 9.5 DBH DRD2 HTR2C
9 regulation of vasoconstriction GO:0019229 9.49 ACE ATP1A2
10 response to pain GO:0048265 9.48 CACNA1A DBH
11 vasoconstriction GO:0042310 9.46 EDNRA SLC6A4
12 behavioral response to ethanol GO:0048149 9.43 DBH DRD2
13 negative regulation of cytosolic calcium ion concentration GO:0051481 9.4 ATP1A2 DRD2
14 regulation of blood pressure GO:0008217 9.33 ACE ATP1A2 EDNRA
15 neuron-neuron synaptic transmission GO:0007270 9.26 CACNA1A DRD2
16 visual learning GO:0008542 9.13 ATP1A2 DBH DRD2
17 response to hypoxia GO:0001666 8.92 DRD2 EDNRA MTHFR SLC6A4

Molecular functions related to Migraine with Aura according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 8.92 ACE ATP1A2 DRD2 HTR2C

Sources for Migraine with Aura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....